WINFIELD S FISHER, MD
Medical Practice at 19 St, Birmingham, AL
License number
Alabama 15451
Category
Medical Practice
Type
Neurological Surgery
Address
Address
619 19Th St SOUTH, Birmingham, AL 35233
Phone
(205) 934-4011
(205) 731-9701
(205) 731-9701
Personal information
See more information about WINFIELD S FISHER at radaris.comName
Address
Phone
3829 Cove Dr, Birmingham, AL 35213
3829 Cove Dr, Mountain Brk, AL 35213
3829 Cove Dr, Birmingham, AL 35213
Organization information
See more information about WINFIELD S FISHER at bizstanding.comUab Hospital - Winfield S Fisher MD
1802 6 Ave S, Birmingham, AL 35233
Categories:
Physicians & Surgeons
Site:
Phone:
(205) 934-9999 (Phone)
Uab Highlands - Winfield S Fisher MD
1201 11 Ave S, Birmingham, AL 35205
Categories:
Physicians & Surgeons
Phone:
(205) 934-9999 (Phone)
University Of Alabama At Birmingham - Winfield S Fisher Iii MD
510 20 St S #SOT, Birmingham, AL 35233
Categories:
General Surgeons, Neurology Physicians & Surgeons, Physicians & Surgeons
Phone:
(205) 996-7170 (Phone)
Winfield S Fisher Iii MD
Kirklin Clinic, Birmingham, AL 35233
Categories:
General Surgeons, Physicians & Surgeons
Phone:
(205) 934-7170 (Phone)
Professional information
Winfield S Fisher, Birmingham AL
Specialties:
Neurosurgeon
Address:
510 20Th St S, Birmingham, AL 35233
619 19Th St S, Birmingham, AL 35233
619 19Th St S, Birmingham, AL 35233
Education:
Saint Louis University, School of Medicine - Doctor of Medicine*
Mount Washington Pediatric Hospital - Residency - Neurological Surgery*
Mount Washington Pediatric Hospital - Residency - Neurological Surgery*
Board certifications:
American Board of Neurological Surgery Certification in Neurological Surgery*
Method For Reducing Obstructive Hydrocephalus
US Patent:
2006021, Sep 21, 2006
Filed:
Jun 3, 2003
Appl. No.:
10/516899
Inventors:
Jay Meythaler - Grosse Pointe Farms MI, US
Winfield Fisher - Birmingham AL, US
Winfield Fisher - Birmingham AL, US
International Classification:
A61K 38/48
US Classification:
424094630, 424094640
Abstract:
A process for reducing cerebrospinal fluid flow obstruction includes the administration of a therapeutic dose of a clot-reducing agent to a subject having preconditions or obstructive hydrocephalus symptoms. The dose is maintained within the subject for a period of time sufficient to reduce cerebrospinal fluid flow obstruction. The clot-reducing agent includes a plasminogen activator, a defibrinogenic agent, an anticoagulant, a platelet inhibitor and a combination thereof. A commercial kit is provided, containing a clot-reducing agent, an administering apparatus, together with instructions for use of the kit.